Exicure Inc
NASDAQ:XCUR
Intrinsic Value
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. [ Read More ]
The intrinsic value of one XCUR stock under the Base Case scenario is 2.907 USD. Compared to the current market price of 0.515 USD, Exicure Inc is Undervalued by 82%.
Valuation Backtest
Exicure Inc
Run backtest to discover the historical profit from buying and selling XCUR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Exicure Inc
Current Assets | 3.7m |
Cash & Short-Term Investments | 2.3m |
Other Current Assets | 1.4m |
Non-Current Assets | 13.9m |
Long-Term Investments | 2m |
PP&E | 8.7m |
Other Non-Current Assets | 3.2m |
Current Liabilities | 1.4m |
Accounts Payable | 300k |
Accrued Liabilities | 1.1m |
Non-Current Liabilities | 6.5m |
Other Non-Current Liabilities | 6.5m |
Earnings Waterfall
Exicure Inc
Revenue
|
23.8m
USD
|
Operating Expenses
|
-20.6m
USD
|
Operating Income
|
3.2m
USD
|
Other Expenses
|
-130k
USD
|
Net Income
|
3.1m
USD
|
Free Cash Flow Analysis
Exicure Inc
XCUR Profitability Score
Profitability Due Diligence
Exicure Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Exicure Inc's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
XCUR Solvency Score
Solvency Due Diligence
Exicure Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Exicure Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XCUR Price Targets Summary
Exicure Inc
According to Wall Street analysts, the average 1-year price target for XCUR is 2 USD .
Ownership
XCUR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
XCUR Price
Exicure Inc
Average Annual Return | -51.36% |
Standard Deviation of Annual Returns | 39.64% |
Max Drawdown | -100% |
Market Capitalization | 4.4m USD |
Shares Outstanding | 8 648 310 |
Percentage of Shares Shorted | 2.39% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 47 full-time employees. The company went IPO on 2018-05-09. The firm is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The firm develops XCUR-FXN, which is a spherical nucleic acid (SNA) -based therapeutic candidate for the treatment of Friedreich’s ataxia (FA). XCUR-FXN through its SNA technology incorporates more than one active oligonucleotides in a single SNA molecule. The Company’s therapeutic candidate cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9) agonist designed for immuno-oncology applications utilizing its SNA technology. AST-008 is in a Phase I b/II clinical trial in patients with advanced solid tumors. TLR9 agonists binds to and activate TLR9.
Contact
IPO
Employees
Officers
The intrinsic value of one XCUR stock under the Base Case scenario is 2.907 USD.
Compared to the current market price of 0.515 USD, Exicure Inc is Undervalued by 82%.